Jan 17, 2024 13:18
ESLA - Estrella Immunopharma, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 1.62 0.08 (4.93%) | --- | --- | 0.0 (0.0%) | 0.0 (0.0%) | 0.03 (1.82%) | 0.0 (0.0%) | 0.0 (0.0%) |
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.15
- Diluted EPS:
- -0.15
- Basic P/E:
- -11.3327
- Diluted P/E:
- -11.3327
- RSI(14) 1m:
- 100.0
- VWAP:
- 1.7
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|